PITTSBURGH, May 25 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Temazepam Capsules USP, 7.5 mg.
This additional strength, which had U.S. sales of approximately $56 million for the 12 months ending March 31, 2010, according to IMS Health, complements Mylan’s already approved and marketed strengths, which are therapeutically equivalent to Mallinckrodt‘s Restoril® 15 mg, 22.5 mg and 30 mg for the short-term treatment of insomnia. The product is available for immediate shipment.
Currently, Mylan has 142 ANDAs pending FDA approval representing $95.6 billion in annual brand sales, according to IMS Health. Thirty-seven of these pending ANDAs are potential first-to-file opportunities, representing $19.6 billion in annual brand sales, for the 12 months ending Dec. 31, 2009, according to IMS Health.
Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry’s broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world’s largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit www.mylan.com.
SOURCE Mylan Inc.
